Perinatal Research on Improving Sleep and Mental Health (PRISM)
Primary Purpose
Insomnia, Depression
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Digital CBT-I
Digital SHE
Sponsored by
About this trial
This is an interventional prevention trial for Insomnia
Eligibility Criteria
Inclusion Criteria:
- Pregnant 14-28 weeks gestation
- 18 years or older
- Daily access to a web-enabled computer, smart phone, or tablet
- Current elevated insomnia symptom severity and insomnia disorder
- English speaking
Exclusion Criteria:
- Current major depression
- Taking or planning to take antidepressant medication (ADM)
- Other diagnosed or suspected sleep disorder
- Other psychiatric or medical issues (e.g., bipolar disorder, active suicidality, bed rest)
- Night shift worker
Sites / Locations
- University of California, San FranciscoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Digital cognitive behavior therapy for insomnia (CBT-I)
Digital sleep hygiene education (SHE)
Arm Description
Outcomes
Primary Outcome Measures
Incidence of perinatal depression, as assessed by the Structured Clinical Interview for the DSM-5 (SCID)
This is a binary outcome that measures whether a participant experienced a depressive episode at any point since randomization.
Secondary Outcome Measures
Change in depressive symptom severity from baseline to 12 months postpartum, as assessed by the Edinburgh Postnatal Depression Scale (EPDS)
The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30, with higher scores indicating greater depressive symptom severity.
Change in depressive symptom severity from baseline to 12 months postpartum, as assessed by the Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9) score ranges from 0 to 27, with higher scores indicating greater depressive symptom severity.
Change in suicidal ideation severity, as rated by the C-SSRS
The Columbia Suicide Severity Rating Scale suicidal ideation score ranges from 1-5, with greater scores indicating more severe ideation, based on the following categories:
- Wish to be Dead
- Non-specific Active Suicidal Thoughts
- Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
- Active Suicidal Ideation with Some Intent to Act, without Specific Plan
- Active Suicidal Ideation with Specific Plan and Intent
Change in anxiety symptom severity, as assessed by the GAD-7
The Generalized Anxiety Disorder-7 score ranges from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Change in prenatal insomnia symptom severity as a mediator of the effect of digital CBT-I on perinatal depression, as assessed by the ISI
The Insomnia Severity Index (ISI) score ranges from 0 to 28, with higher scores indicating greater insomnia severity.
Baseline depressive symptom severity as a moderator, as assessed by the EPDS
The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30, with higher scores indicating greater depressive symptom severity.
Baseline depressive symptom severity as a moderator, as assessed by the PHQ-9
The Patient Health Questionnaire-9 (PHQ-9) score ranges from 0 to 27, with higher scores indicating greater depressive symptom severity.
Full Information
NCT ID
NCT05596318
First Posted
October 24, 2022
Last Updated
November 2, 2022
Sponsor
University of California, San Francisco
Collaborators
Stanford University
1. Study Identification
Unique Protocol Identification Number
NCT05596318
Brief Title
Perinatal Research on Improving Sleep and Mental Health
Acronym
PRISM
Official Title
Efficacy of Digital Cognitive Behavior Therapy for Insomnia for the Prevention of Perinatal Depression
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 2, 2022 (Actual)
Primary Completion Date
April 2027 (Anticipated)
Study Completion Date
April 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
Stanford University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this clinical trial is to compare two sleep programs in pregnant people with insomnia. The main questions it aims to answer are:
What is the efficacy of digital cognitive behavioral therapy for insomnia (CBT-I) versus digital sleep hygiene education (SHE) for preventing perinatal depression?
Is the effect of digital CBT-I on perinatal depression mediated through prenatal insomnia symptom improvement?
Is the effect of digital CBT-I on perinatal depression moderated by baseline depressive symptom severity?
Participants will receive one of two sleep programs - SHE or CBT-I. Both involve six weekly online sessions. Participants will complete surveys and interviews until 1 year postpartum.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia, Depression
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
498 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Digital cognitive behavior therapy for insomnia (CBT-I)
Arm Type
Experimental
Arm Title
Digital sleep hygiene education (SHE)
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Digital CBT-I
Other Intervention Name(s)
Sleepio
Intervention Description
The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
Intervention Type
Device
Intervention Name(s)
Digital SHE
Intervention Description
The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
Primary Outcome Measure Information:
Title
Incidence of perinatal depression, as assessed by the Structured Clinical Interview for the DSM-5 (SCID)
Description
This is a binary outcome that measures whether a participant experienced a depressive episode at any point since randomization.
Time Frame
Baseline to 12 months postpartum
Secondary Outcome Measure Information:
Title
Change in depressive symptom severity from baseline to 12 months postpartum, as assessed by the Edinburgh Postnatal Depression Scale (EPDS)
Description
The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30, with higher scores indicating greater depressive symptom severity.
Time Frame
Baseline to 12 months postpartum
Title
Change in depressive symptom severity from baseline to 12 months postpartum, as assessed by the Patient Health Questionnaire-9 (PHQ-9)
Description
The Patient Health Questionnaire-9 (PHQ-9) score ranges from 0 to 27, with higher scores indicating greater depressive symptom severity.
Time Frame
Baseline to 12 months postpartum
Title
Change in suicidal ideation severity, as rated by the C-SSRS
Description
The Columbia Suicide Severity Rating Scale suicidal ideation score ranges from 1-5, with greater scores indicating more severe ideation, based on the following categories:
- Wish to be Dead
- Non-specific Active Suicidal Thoughts
- Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
- Active Suicidal Ideation with Some Intent to Act, without Specific Plan
- Active Suicidal Ideation with Specific Plan and Intent
Time Frame
Baseline to 12 months postpartum
Title
Change in anxiety symptom severity, as assessed by the GAD-7
Description
The Generalized Anxiety Disorder-7 score ranges from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Time Frame
Baseline to 12 months postpartum
Title
Change in prenatal insomnia symptom severity as a mediator of the effect of digital CBT-I on perinatal depression, as assessed by the ISI
Description
The Insomnia Severity Index (ISI) score ranges from 0 to 28, with higher scores indicating greater insomnia severity.
Time Frame
Baseline to 10 weeks post-randomization (mediator)
Title
Baseline depressive symptom severity as a moderator, as assessed by the EPDS
Description
The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30, with higher scores indicating greater depressive symptom severity.
Time Frame
Baseline
Title
Baseline depressive symptom severity as a moderator, as assessed by the PHQ-9
Description
The Patient Health Questionnaire-9 (PHQ-9) score ranges from 0 to 27, with higher scores indicating greater depressive symptom severity.
Time Frame
Baseline
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant 14-28 weeks gestation
18 years or older
Daily access to a web-enabled computer, smart phone, or tablet
Current elevated insomnia symptom severity and insomnia disorder
English speaking
Exclusion Criteria:
Current major depression
Taking or planning to take antidepressant medication (ADM)
Other diagnosed or suspected sleep disorder
Other psychiatric or medical issues (e.g., bipolar disorder, active suicidality, bed rest)
Night shift worker
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer N Felder, PhD
Phone
415-476-7014
Email
jennifer.felder@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer N Felder, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94118
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Felder, PhD
Phone
415-476-7014
Email
prismstudy@ucsf.edu
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
We will share data via the National Database for Clinical Trials related to Mental Illness (NDCT), which is a secure platform for scientific collaboration and data-sharing
IPD Sharing Time Frame
Annually
Learn more about this trial
Perinatal Research on Improving Sleep and Mental Health
We'll reach out to this number within 24 hrs